2 results
10-Q
2024 Q1
NAMS
NewAmsterdam Pharma Company NV
8 May 24
Quarterly report
4:30pm
Accrued expenses and other current liabilities consisted of the following:
(in thousands of USD) | March 31, 2024 | December 31, 2023 | ||||||
Accrued research and development materials and services | 7,190 | 5,945 | ||||||
Accrued compensation and benefits | 1,105 | 3,384 | ||||||
Accrued professional fees and other | 1,675 | 2,069 | ||||||
Total accrued expenses and other current liabilities | 9,970 | 11,398 |
10-K
2023 FY
NAMS
NewAmsterdam Pharma Company NV
28 Feb 24
Annual report
8:00am
Accrued expenses and other current liabilities consisted of the following:
As at December 31, | ||||||||
(in thousands of USD) | 2023 | 2022 | ||||||
Accrued research and development materials and services | 5,945 | 1,137 | ||||||
Accrued compensation and benefits | 3,384 | 1,998 | ||||||
Accrued professional fees and other | 2,069 | 2,982 | ||||||
Total accrued expenses and other current liabilities | 11,398 | 6,117 |
- Prev
- 1
- Next